153 reports of this reaction
1.5% of all TASIMELTEON reports
#15 most reported adverse reaction
INITIAL INSOMNIA is the #15 most commonly reported adverse reaction for TASIMELTEON, manufactured by Vanda Pharmaceuticals Inc.. There are 153 FDA adverse event reports linking TASIMELTEON to INITIAL INSOMNIA. This represents approximately 1.5% of all 9,924 adverse event reports for this drug.
Patients taking TASIMELTEON who experience initial insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INITIAL INSOMNIA is a less commonly reported adverse event for TASIMELTEON, but still significant enough to appear in the safety profile.
In addition to initial insomnia, the following adverse reactions have been reported for TASIMELTEON:
The following drugs have also been linked to initial insomnia in FDA adverse event reports:
INITIAL INSOMNIA has been reported as an adverse event in 153 FDA reports for TASIMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
INITIAL INSOMNIA accounts for approximately 1.5% of all adverse event reports for TASIMELTEON, making it a notable side effect.
If you experience initial insomnia while taking TASIMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.